Biomarin Pharma Earnings, Revenue Beat in Q2
2022.08.03 23:50
Biomarin Pharma Earnings, Revenue Beat in Q2
Investing.com – Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday second quarter earnings that beat analysts’ forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.15 on revenue of $533.8M. Analysts polled by Investing.com anticipated EPS of $0.0257 on revenue of $520.35M.
Biomarin Pharma shares are up 0.06% from the beginning of the year, still down 6.16% from its 52 week high of $94.20 set on February 10. They are outperforming the Nasdaq which is down 19.03% from the start of the year.
Biomarin Pharma shares lost 0.21% in after-hours trade following the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma’s report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
